View clinical trials related to Malignant Advanced Solid Tumor.
Filter by:Phase I dose escalating trial. Primary objectives of this study are to assess the safety and tolerability of Simmiparib following single and multiple oral doses in patients with advanced solid malignancies, to determine the maximum tolerance dose (MTD) and dose limiting toxicity (DLT), and pharmacokinetic profile. The Secondary objective is to observe the preliminary antitumor effect of Simmiparib.